JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Madrigal Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

424.5 1.94

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

413

Max

424.77

Pagrindiniai rodikliai

By Trading Economics

Pajamos

31M

-42M

Pardavimai

76M

213M

Pelnas, tenkantis vienai akcijai

-1.9

Pelno marža

-19.869

Darbuotojai

528

EBITDA

31M

-39M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+21.75% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

2.9B

9.8B

Ankstesnė atidarymo kaina

422.56

Ankstesnė uždarymo kaina

424.5

Naujienos nuotaikos

By Acuity

50%

50%

163 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Madrigal Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-23 20:49; UTC

Uždarbis

Correction to Thermo Fisher Article on Oct. 22

2025-10-23 23:51; UTC

Rinkos pokalbiai

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

2025-10-23 23:49; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-23 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

2025-10-23 23:37; UTC

Rinkos pokalbiai

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

2025-10-23 22:58; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-10-23 22:57; UTC

Rinkos pokalbiai

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

2025-10-23 22:49; UTC

Įsigijimai, susijungimai, perėmimai

How Trump Sparked a New Era of State Capitalism -2-

2025-10-23 22:49; UTC

Įsigijimai, susijungimai, perėmimai

How Trump Sparked a New Era of State Capitalism -- Barrons.com

2025-10-23 22:17; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

2025-10-23 21:41; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

2025-10-23 21:05; UTC

Uždarbis

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

2025-10-23 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-10-23 20:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-10-23 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-23 20:35; UTC

Uždarbis

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

2025-10-23 20:28; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

2025-10-23 20:15; UTC

Rinkos pokalbiai
Uždarbis

Global Commodities Roundup: Market Talk

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q Adj EPS $1.71

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q Sales $5.52B

2025-10-23 20:10; UTC

Uždarbis

Newmont Mining 3Q EPS $1.67

2025-10-23 20:09; UTC

Uždarbis

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

2025-10-23 20:07; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-10-23 20:07; UTC

Rinkos pokalbiai
Uždarbis

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

2025-10-23 20:07; UTC

Uždarbis

Blackstone Looks to IPOs for Investment Exits -- Update

2025-10-23 20:05; UTC

Uždarbis

Intel 3Q Gross Margin 38.2% >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

2025-10-23 20:04; UTC

Uždarbis

Intel: 4Q Guidance Excludes Altera >INTC

2025-10-23 20:04; UTC

Uždarbis

Intel Sees 4Q Adj EPS 8c >INTC

Akcijų palyginimas

Kainos pokytis

Madrigal Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

21.75% į viršų

12 mėnesių prognozė

Vidutinis 506.43 USD  21.75%

Aukščiausias 590 USD

Žemiausias 266 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Madrigal Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

16 ratings

14

Pirkti

1

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

263.2 / 277.1Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

163 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat